United Therapeutics (UTHR) Revenue by Segment

History

Date	Tyvaso	Remodulin	Orenitram	Unituxin	Other	Adcirca
Dec 31, 2024	1.62B	538.10M	434.30M	238.70M	17.20M	23.80M
Sep 30, 2024	1.56B	518.70M	410.60M	225.40M	15.60M	25.90M
Jun 30, 2024	1.45B	521.50M	389.40M	215.60M	-	26.20M
Mar 31, 2024	1.37B	501.40M	377.40M	208.20M	12.00M	28.00M
Dec 31, 2023	1.23B	494.80M	359.40M	198.90M	8.30M	28.90M
Sep 30, 2023	1.13B	502.20M	351.10M	181.40M	8.20M	32.50M
Jun 30, 2023	1.06B	485.10M	346.60M	176.20M	-	35.90M
Mar 31, 2023	939.40M	489.90M	330.50M	176.40M	6.30M	38.80M
Dec 31, 2022	873.00M	500.20M	325.10M	182.90M	13.80M	41.30M
Sep 30, 2022	797.20M	496.00M	321.60M	196.20M	-	39.00M
Jun 30, 2022	703.70M	507.40M	319.30M	205.40M	-	42.90M
Mar 31, 2022	656.50M	515.20M	316.50M	214.00M	10.00M	56.10M
Dec 31, 2021	607.50M	513.70M	306.10M	202.30M	-	55.90M
Sep 30, 2021	572.70M	523.30M	307.80M	182.00M	-	69.40M
Jun 30, 2021	538.00M	522.40M	297.30M	164.30M	-	68.60M
Mar 31, 2021	503.40M	501.60M	296.50M	140.20M	-	64.40M
Dec 31, 2020	483.30M	516.70M	293.10M	122.90M	-	67.30M
Sep 30, 2020	443.00M	496.20M	270.00M	126.80M	-	73.50M

Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.